Bio-Techne Corp.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $181.9M | $73.4M | $168.1M | $285.3M | $272.1M | $140.4M | $229.3M | $96.1M |
| Depreciation & Amortization | $97.4M | $109.9M | $111.7M | $107.2M | $101.1M | $87.7M | $82.7M | $78.2M |
| Depreciation | $36.2M | $34.6M | $31.9M | $29.7M | — | — | — | — |
| Amortization | $61.8M | $76.0M | $79.9M | $77.5M | $74.1M | $64.9M | $61.1M | $58.7M |
| Stock-Based Compensation | $41.4M | $40.8M | $38.0M | $39.2M | $42.2M | $49.0M | $32.4M | $32.3M |
| Net Cash from Operating Activities | $292.1M | $287.6M | $299.0M | $254.4M | $325.3M | $352.2M | $205.2M | $181.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $28.9M | $31.0M | $62.9M | $38.2M | $44.9M | $44.3M | $51.7M | $25.4M |
| Business Acquisitions | — | — | $169.7M | $101.2M | — | $225.4M | $0 | $289.5M |
| Net Cash from Investing Activities | $-18.2M | $-35.2M | $-203.0M | $-265.6M | $-96.9M | $-243.5M | $27.1M | $-336.8M |
| Financing Activities | ||||||||
| Dividends Paid | $49.9M | $50.4M | $50.4M | $50.3M | $50.2M | $49.6M | $48.9M | $48.4M |
| Stock Repurchases | $41.7M | $275.7M | $80.0M | $19.6M | $161.0M | $43.2M | $50.1M | $15.4M |
| Net Cash from Financing Activities | $-169.1M | $-253.9M | $-122.4M | $22.6M | $-242.9M | $-62.6M | $-183.8M | $134.4M |
| Net Change in Cash | $102.5M | $10.4M | $-28.8M | $8.0M | $-26.5M | $52.5M | $45.7M | $-21.1M |
| Free Cash Flow | $263.2M | $256.6M | $236.1M | $216.1M | $280.4M | $307.9M | $153.5M | $156.2M |